L. Dirix - Concepedia

Author

L. Dirix

GZA Ziekenhuizen Campus Sint-Augustinus

Also Known As

L Dirix, L Y Dirix, L. Dirix, L.Y. Dirix, LY Dirix, PB Vermeulen

Publications

640

Citations

H-Index

Concepts

All Affiliations

GZA Ziekenhuizen Campus Sint-Augustinus Antwerp University Hospital Institut Jules Bordet University of Antwerp Universitair Ziekenhuis Leuven

About

L. Dirix is an author at GZA Ziekenhuizen Campus Sint-Augustinus specializing in medicine, radiation oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	471
2	Immunology	3	3	249
3	Health Sciences	1	1	109
4	Social Sciences	1	1	12
5	Neurology	1	1	12

L. Dirix

Publications

561

Citations

H-Index

Page 1

	Year	Citations
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer Marcus Schmidt, M. E. Scheulen, Christian Dittrich, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicineImmunologyImmune Checkpoint Inhibitor	2009	130
Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU) Eric Van Cutsem, David Cunningham, W.W. ten Bokkel Huinink, European Journal of Cancer Health SciencesMedicinePharmacologyColorectal CancerPharmacotherapy	1999	109
Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial L. Dirix, István Takács, Petros Nikolinakos, Cancer Research Breast OncologyImmunologyProgrammed Death-1 ReceptorPathologyImmunoediting	2016	108
Intraoperative sentinel node identification with Technetium-99m-labeled nanocolloid in patients with cancer of the uterine cervix: A feasibility study Peter A. van Dam, Jan Hauspy, T. Vanderheyden, International Journal of Gynecological Cancer	2003	80
5001 ORAL Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450g/BO21976) Sara A. Hurvitz, L. Dirix, Judit Kocsis, European Journal of Cancer Oral Trastuzumab EmtansineOncologyBreast OncologyPrimary ResultsMedicine	2011	54
Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. HJ Burstein, Yan Sun, AR Tan, Cancer Research Erbb2 Gene AmplificationBreast OncologyOncologyMedicineCancer Cell Biology	2009	47
Deep cerebral invasion by basal cell carcinoma of the scalp Paul M. Parizel, L. Dirix, D. Van den Weyngaert, Neuroradiology Neuro-oncologyTumor InnervationNeuroanatomyDeep Cerebral InvasionBrain Tumor Biology	1996	12
Real-time RT-PCR of CD146 and VE-cadherin mRNA to detect circulating endothelial cells in peripheral blood of patients with breast cancer L. Dirix, Ilse Van der Auwera, H. Elst, European Journal of Cancer Supplements Tumor BiologyBreast OncologyAngiogenesisEndothelial CellsCancer Detection	2006	11
The role of ifosfamide in the treatment of sarcomas. L. Dirix, van Oosterom At PubMed	1989	10

Page 1